Over the last year, Throne has made significant progresses in the FDA-approved clinical trials of Stem Cell Educator therapy for the treatment of type 1 diabetes (T1D), alopecia areata (AA) and other inflammation/autoimmune-associated diseases. In this Holiday season, we sincerely appreciate all staffs, collaborators, shareholders, investors, advisers, regulators, patients, and their families for their long-term supports and prayers!
Best Wishes and Happy New Year to All!
Yong Zhao, MD, PhD